To fill influenza pollen shortage, Hong Kong officials consider doses meant for southern hemisphere

Hong Kong health officials can introduce influenza vaccines intended for the southern hemisphere in light of the city's influenza pollen shortage this year, by private doctors telling they had no further of the immunity-Battling substance for their patients. The Inc. said it would in the coming weeks discuss by its headquarters in France the potential of introducing southern hemisphere vaccines to the city. "The composition of vaccines recommended for the southern hemisphere basically is sosimilar to those of the northern hemisphere," Wong said. The 2 vaccines each contain 4 influenza strains & are similar, except which the southern hemisphere pollen contains the Singapore H3N2-such as strain instead of the Hong Kong H3N2-such as strain found in the northern hemisphere pollen. "The 1 for the southern hemisphere perhaps be slightly better than the 1 for the northern hemisphere, however the difference perhaps not be significant."Chow said a man would not must receive a jab of the southern hemisphere pollen if he or she had indeed received 1 from the northern hemisphere.

As raging influenza epidemic spreads, Sanofi Pasteur targets further efficient cell-based Global pollen

Sanofi Pasteur has signed a bargain by SK Chemicals to license cell culture pollen technology as the raging influenza epidemic in the U.S., 1 of the worse in recent history, highlights the necessity for a Global pollen & further potent influenza bullets produced in cells instead of eggs. Sanofi does not just have any vaccines in mind, however 1 in particular—the Extremely -called "Global" influenza pollen, that could prevent versus many strains of influenza virus & does not necessity to be updated seasonally. Utilizing the cell-based technology, where influenza pollen is made in animal cells, SK has indeed released a trivalent influenza pollen in 2015 & a quadrivalent version in 2016. linked: Google, Sequoia back Oxford Global influenza pollen developer VaccitechCurrently Seqirus, that purveys Flucelvax, has the just Food and Drug Administration-confirmed mammalian cell-based influenza bullet. As for the race to a Global influenza pollen, Sanofi is competing by Johnson & Johnson, FluGen, BiondVax & University of Oxford spinout Vaccitech, that soon secured $27 mn in series A backed by GV & others.

Debunking influenza pollen myths

as mentioned in & yet, people continue resist the influenza bullet. "This year I didn't get my influenza bullet because I simply didn't make the time," Sullivan said. "I going to miss my friend Extremely much, she was a dynamic captivating individual, I'll miss her forever."NBC break news reports 1 of the biggest myths about the influenza pollen is which it going to people ill. Another myth is which people who are allergic to eggs ought not get a influenza bullet. Even though this year's pollen isn't as efficient, if you do get sick, it could lower the length & severity of the influenza.

scholars company closer to Global influenza pollen as virus wreaks havoc on North US

This year's influenza season has broken records in terms of hospitalizations & dyinges across North US, that has scholars circling back to the potential of a Global influenza pollen. A large factor in this year's aggressive influenza season has been the low effectiveness of the influenza vaccines in both Canada & the U.S.. "To some people, a Global pollen really means Global. A 2nd research launched in January has a further hopeful outlook on the timeline for a Global influenza pollen. "A few years ago, there were a lot of Global influenza pollen strategies in the pre-clinical phase, that were looking sopromising.

Sanofi & SK Chemicals sign influenza pollen bargain

Sanofi SA's (SAN.FR) vaccines division, Sanofi Pasteur, & SK Chemicals Co. Ltd. (285130.SE) have signed a licensing licence for influenza pollen technology, SK Chemicals said on Monday. Under the terms of the licence, Sanofi Pasteur going to pay SK Chemicals up to $155 mn, including milestone payments, to license SK Chemicals's cell-culture based manufacturing technology for influenza vaccines. Sanofi Pasteur is licensing the technology for Utilize in its efforts to develop a broadly protective influenza pollen, SK Chemicals said. Broadly protective influenza vaccines are designed to prevent versus many different strains of the virus. Sanofi Pasteur is the world's largest Maker of influenza pollen, according to its webpage.

collected by :Lucy William